Group
CSF1R targeting TKI
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Mechanism of Action | CSF1R inhibitor |
| Drugs in group | Vimseltinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically radiosensitizing (depletes/reprograms protective M2 TAMs), not a DNA-level sensitizer (Almahariq et al., In Vivo, 2021; Barry et al., Nature Reviews Cancer, 2023). No in-field DNA sensitization; the relevant class caution is hepatological adverse events rather than radiation-side-effects potentiation.
The data above refer to patients treated with CSF1R targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.